Table 2. Comparison of clinicopathologic factors between patients who underwent curative-intent resection (<3cm, N0) and curative-intent transplantation, excluding patients primary sclerosing cholangitis.
| Variable | Resection Curative, <3cm, N0 (n=56, 78%) |
Transplant Non-PSC (n=16, 22%) |
p-value |
|---|---|---|---|
| Age (yrs), median (IQR) | 67 (58 – 74) | 60 (50 – 66) | 0.01 |
|
| |||
| Male, n (%) | 32 (57) | 11 (69) | 0.56 |
|
| |||
| BMI (kg/m2), median (IQR) | 26 (23 – 29) | 25 (23 – 28) | 0.51 |
|
| |||
| Race, n (%) | 0.29 | ||
| White | 41 (73) | 13 (81) | |
| African-American | 5 (9) | 2 (13) | |
| Other | 10 (18) | 1 (6) | |
|
| |||
| ASA Class, n (%) | <0.001 | ||
| 1 / 2 | 15 (33) | 1 (6) | |
| 3 / 4 | 30 (67) | 15 (94) | |
|
| |||
| Preoperative Labs, median (IQR) | |||
| Bilirubin (mg/dL) | 2.0 (0.9 – 4.2) | 0.7 (0.4 – 1.6) | 0.008 |
| Albumin (g/dL) | 3.4 (3.1 – 3.8) | 3.6 (3.0 – 3.8) | 0.67 |
| Creatinine (mg/dL) | 0.8 (0.7 – 0.9) | 0.7 (0.6 – 0.9) | 0.21 |
| INR | 1.0 (1.0 – 1.1) | 1.1 (1.0 – 1.2) | 0.031 |
|
| |||
| Type of Resection, n (%) | |||
| Hemi-Hepatectomy + CBD Resection | 32 (58) | ||
| Extended Hepatectomy + CBD Resection | 17 (30) | — | — |
| Trisectionectomy + CBD Resection | 7 (12) | ||
|
| |||
| Major Complication, n (%) | 22 (42) | 4 (25) | 0.38 |
| Postoperative Liver Failure | 4 (7) | 2 (23) | 0.61 |
| 30-day Mortality | 6 (11) | 1 (6) | 1.00 |
| 90-day Mortality | 8 (14) | 1 (6) | 0.67 |
|
| |||
| Length of Stay (days), median (IQR) | 9 (7 – 17) | 7 (5 – 13) | 0.17 |
|
| |||
| Pathologic complete response, n (%) | — | 0 (0) | — |
|
| |||
| Final margin status, n (%) | 0.01 | ||
| R0 | 39 (70) | 13 (81) | |
| R1 | 17 (30) | 3 (19) | |
|
| |||
| Tumor size, median (IQR) | 2.0 (1.5 – 2.5) | 2.9 (1.2 – 5.5) | 0.08 |
|
| |||
| AJCC T-Stage, n (%) | 0.09 | ||
| Tis/T1 | 9 (24) | 5 (31) | |
| T2 | 24 (62) | 6 (38) | |
| T3 | 5 (13) | 3 (19) | |
| T4 | 0 (0) | 2 (13) | |
|
| |||
| Blumgart T-Stage, n (%) | 0.19 | ||
| T1 | 20 (40) | 9 (60) | |
| T2 | 14 (28) | 1 (7) | |
| T3 | 16 (32) | 5 (33) | |
|
| |||
| Bismuth Classification, n (%) | <0.001 | ||
| Type I | 3 (6) | 0 (0) | |
| Type II | 6 (12) | 9 (60) | |
| Type III | 28 (54) | 1 (7) | |
| Type IV | 15 (29) | 5 (33) | |
|
| |||
| Grade, n (%) | 0.10 | ||
| Low | 11 (22) | 0 (0) | |
| Intermediate | 31 (61) | 9 (64) | |
| High | 9 (18) | 5 (36) | |
|
| |||
| Lymphovascular invasion, n (%) | 14 (30) | 5 (31) | 1.00 |
|
| |||
| Perineural invasion, n (%) | 38 (81) | 8 (50) | 0.04 |
|
| |||
| Lymph nodes retrieved, n (%) | 56 (100) | 14 (88) | 0.05 |
|
| |||
| # Lymph nodes retrieved, median (IQR) | 3 (2 – 6) | 4 (2 – 6) | 0.85 |
|
| |||
| Lymph node positive, n (%) | 0 (0) | 3 (19) | 0.009 |
|
| |||
| Neoadjuvant therapy, n (%) | |||
| Chemotherapy | 3 (5) | 16 (100) | <0.001 |
| Radiation | 2 (4) | 16 (100) | <0.001 |
|
| |||
| Adjuvant therapy, n (%) | |||
| Chemotherapy | 18 (36) | 0 (0) | 0.003 |
| Radiation | 13 (26) | 0 (0) | 0.03 |
|
| |||
| Recurrence, n (%) | 15 (29) | 5 (31) | 1.00 |
| Locoregional only | 4 (31) | 1 (20) | 1.00 |
| Distant | 9 (69) | 4 (80) | |
BMI, mass body index; IQR, interquartile range; ASA, American Society of Anesthesiologists; INR, international normalized ratio; CBD, common bile duct; AJCC, American Joint Committee on Cancer